Anticancer Res

1. HOLM I, Hernroth B, Rosander A, Tassidis H, et al
   Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate Cancer Cells.
   Anticancer Res. 2024;44:953-962.
   

   >> Share

   
   
2. YAMAMICHI G, Kato T, Watabe T, Hatano K, et al
   Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
   Anticancer Res. 2024;44:879-888.
   

   >> Share

   
   

   
   BJU Int

3. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
   During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
   BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
   

   >> Share

   
   
4. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
   Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
   BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.
   

   >> Share

   
   
5. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
   The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
   BJU Int. 2024;133 Suppl 3:39-47.
   

   >> Share

   
   
6. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
   How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
   BJU Int. 2024;133 Suppl 3:13-14.
   

   >> Share

   
   

   
   BMC Cancer

7. HUANG H, Liu Y, Wen Z, Chen C, et al
   Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis.
   BMC Cancer. 2024;24:261.
   

   >> Share

   
   
8. CHEN J, Yu F, He G, Hao W, et al
   A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
   BMC Cancer. 2024;24:254.
   

   >> Share

   
   

   
   Br J Cancer

9. EBERLEIN C, Williamson SC, Hopcroft L, Ros S, et al
   Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
   Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02614.
   

   >> Share

   
   

   
   Br J Radiol

10. MCDAID L, Clough A, Benson KR, Nelder C, et al
    Geometric distortion caused by metallic femoral head prosthesis in prostate cancer imaging on an MR linac: in-vivo measurements of spatial deformation.
    Br J Radiol. 2024 Feb 24:tqae044. doi: 10.1093.
    

    >> Share

    
    

    
    Cancer

11. WALBURN T, Chen MH, Loffredo M, McMahon E, et al
    Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274.
    

    >> Share

    
    
12. FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al
    The 340B Program and oral specialty drugs for advanced prostate cancer.
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262.
    

    >> Share

    
    

    
    Cancer Lett

13. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    

    >> Share

    
    
14. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

15. NEILSEN BK, Ma TM, Akingbemi WO, Neylon J, et al
    Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Rad
    Int J Radiat Oncol Biol Phys. 2024;118:986-997.
    

    >> Share

    
    
16. BESUGLOW J, Tessonnier T, Mein S, Eichkorn T, et al
    Understanding RBE and clinical outcome of prostate cancer therapy using particle irradiation: analysis of tumor control probability with mMKM.
    Int J Radiat Oncol Biol Phys. 2024 Feb 27:S0360-3016(24)00331.
    

    >> Share

    
    

    
    J Magn Reson Imaging

17. CHONG JJR
    Editorial for "Development and Validation of Interpretable Machine Learning Models for Clinically Significant Prostate Cancer Diagnosis in Patients With Lesions of PI-RADS v2.1 Score >/=3".
    J Magn Reson Imaging. 2024 Feb 29. doi: 10.1002/jmri.29277.
    

    >> Share

    
    

    
    J Nucl Med

18. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    

    >> Share

    
    
19. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
    

    >> Share

    
    
20. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    

    >> Share

    
    

    
    J Urol

21. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    J Urol. 2024 Feb 14:101097JU0000000000003891. doi: 10.1097/JU.0000000000003891.
    

    >> Share

    
    
22. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
    J Urol. 2024 Feb 14:101097JU0000000000003890. doi: 10.1097/JU.0000000000003890.
    

    >> Share

    
    
23. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2024 Feb 19:101097JU0000000000003892. doi: 10.1097/JU.0000000000003892.
    

    >> Share

    
    

    
    Lancet Oncol

24. DUAN H, Moradi F, Davidzon GA, Liang T, et al
    (68)Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
    Lancet Oncol. 2024 Feb 26:S1470-2045(24)00069.
    

    >> Share

    
    

    
    PLoS One

25. ZAFEIROPOULOU K, Kalampounias G, Alexis S, Anastasopoulos D, et al
    Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
    PLoS One. 2024;19:e0289904.
    

    >> Share

    
    
26. 
    Retraction: Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy.
    PLoS One. 2024;19:e0299822.
    

    >> Share

    
    

    
    Prostate

27. ALANAZI G, Alsubaie N, Nabi G, Gillingwater TH, et al
    Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy.
    Prostate. 2024;84:491-501.
    

    >> Share

    
    
28. KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al
    Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
    Prostate. 2024 Feb 27. doi: 10.1002/pros.24679.
    

    >> Share

    
    

    
    Ther Adv Urol

29. COQUAN E, Penel N, Lequesne J, Leman R, et al
    Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
    Ther Adv Urol. 2024;16:17562872241229876.
    

    >> Share

    
    

    
    Urology

30. MANDEL AL, Simhal RK, Shah YB, Wang KR, et al
    Racial disparities in diagnosis and treatment of depression Associated with androgen deprivation therapy for prostate cancer.
    Urology. 2024 Feb 21:S0090-4295(24)00094-3. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
31. KHAN HM
    Editorial Commentary on Improving Racial Disparities in Prostate Cancer.
    Urology. 2024 Feb 21:S0090-4295(24)00095-5. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
32. FROEHNER M, Gorner M, Merkle L, Kopka K, et al
    (18)Fluorine prostate-specific membrane antigen 1007 positron emission tomography for high-risk prostate cancer.
    Urology. 2024 Feb 27:S0090-4295(24)00131-6. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share